Vagelos P Roy - Feb 22, 2023 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
Director
Signature
/s/**P. Roy Vagelos
Stock symbol
REGN
Transactions as of
Feb 22, 2023
Transactions value $
-$10,265,116
Form type
4
Date filed
2/24/2023, 03:07 PM
Previous filing
Dec 21, 2022
Next filing
Mar 27, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock +Options Exercise $11,493,275 +42,500 +13.11% $270.43 366,583 Feb 22, 2023 Direct
transaction REGN Common Stock -Tax liability -$21,758,391 -29,005 -7.91% $750.16 337,578 Feb 22, 2023 Direct
transaction REGN Common Stock -Gift $0 -291 -0.23% $0.00 125,752 Jan 4, 2023 by CLAT
holding REGN Common Stock 1,963 Feb 22, 2023 By 401(k) Plan
holding REGN Common Stock 23,461 Feb 22, 2023 by Spouse as Trustee
holding REGN Common Stock 3,609 Feb 22, 2023 by trust for grandch F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) -Options Exercise $0 -42,500 -33.33% $0.00 85,000 Feb 22, 2023 Common Stock 42,500 $270.43 Direct F2

Explanation of Responses:

Id Content
F1 By trusts for the benefit of nine grandchildren of the reporting person, each of which holds 401 shares of Company stock. The reporting person and/or the spouse of the reporting person is the trustee of each such trust.
F2 The stock option award vests in four equal annual installments, commencing one year after the date of grant.